Assessing population immunity in a persistently high-risk area for wild poliovirus transmission in India: a serological study in Moradabad, Western Uttar Pradesh

J Infect Dis. 2014 Nov 1;210 Suppl 1(Suppl 1):S225-33. doi: 10.1093/infdis/jiu204.

Abstract

Background: Moradabad district in Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007. We conducted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in children 6-12 and 36-59 months of age to guide future strategies to interrupt wild poliovirus transmission in high-risk areas.

Methods: Children attending 10 health facilities for minor illnesses who met criteria for study inclusion were eligible for enrollment. We recorded vaccination history, weight, and length and tested sera for neutralizing antibodies to poliovirus types 1, 2, and 3.

Results: Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI], 84%-91%), 70% (95% CI, 66%-75%), and 75% (95% CI, 71%-79%), respectively, among 467 in the younger age group (n=467), compared with 100% (95% CI, 99%-100%), 97% (95% CI, 95%-98%), and 93% (91%-95%), respectively, among 447 children in the older age group (P<.001 for all serotypes).

Conclusions: This seroprevalence study provided extremely useful information that was used by the program in India to guide immunization policies, such as optimizing the use of different OPV formulations in vaccination campaigns and strengthening routine immunization services. Similar surveys in populations at risk should be performed at regular intervals in countries where the risk of persistence or spread of indigenous or imported wild poliovirus is high.

Keywords: Moradabad; OPV formulations; immunization policies; immunogenecity; neutralizing antibodies; seroprevalence; wild poliovirus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood*
  • Child, Preschool
  • Female
  • Humans
  • India / epidemiology
  • Infant
  • Male
  • Poliomyelitis / epidemiology*
  • Poliomyelitis / prevention & control*
  • Poliovirus Vaccine, Oral / administration & dosage
  • Poliovirus Vaccine, Oral / immunology*
  • Seroepidemiologic Studies

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Poliovirus Vaccine, Oral